参考文献/References:
[1]Naimi A,Mohammed RN,Raji A,et al.Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons[J].Cell Commun Signal,2022,20(1):44.[2]Vaddepally RK,Kharel P,Pandey R,et al.Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence[J].Cancers (Basel),2020,12(3):738.[3]Fan SY,Ren HT,Zhao L,et al.Neurological immune-related adverse events associated with immune checkpoint inhibitors:a review of the literature[J].Asia Pac J Clin Oncol,2020,16(6):291-298.[4]Marini A,Bernardini A,Gigli GL,et al.Neurologic adverse events of immune checkpoint inhibitors: a systematic review[J].Neurology,2021,96(16):754-766.[5]Diamanti L,Picca A,Bini P,et al.Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience[J].Neurol Sci，2022,43(3):2031-2041.[6]Cuzzubbo S,Javeri F,Tissier M,et al.Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature[J].Eur J Cancer,2017,73:1-8.[7]Eggermont AM,Chiarion-Sileni V,Grob JJ,et al.Adjuvant ipilimumab versus placebo after complete resection of high-risk stage Ⅲ melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial[J].Lancet Oncol,2015,16(5):522-530.[8]Perrinjaquet C,Desbaillets N,Hottinger AF.Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy[J].Curr Opin Neurol,2019,32(3):500-510.[9]Spain L,Walls G,Julve M,et al.Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature[J].Ann Oncol,2017,28(2):377-385.[10]Zimmer L,Goldinger SM,Hofmann L,et al.Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy[J].Eur J Cancer,2016,60:210-225.[11]Martins F,Sofiya L,Sykiotis GP,et al.Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance[J].Nat Rev Clin Oncol,2019,16(9):563-580.[12]Vogrig A,Mu?觡iz-Castrillo S,Farina A,et al.How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update[J].J Neurol,2022,269(3):1701-1714.[13]Chang H,Shin YW,Keam B,et al.HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor[J].Ann Clin Transl Neurol,2020,7(11):2243-2250.[14]Guidon AC,Burton LB,Chwalisz BK,et al.Consensus disease defnitions for neurologic immune-related adverse events of immune checkpoint inhibitors[J].J Immunother Cancer,2021,9(12):e002890.[15]Wang DY,Salem JE,Cohen JV,et al.Fatal toxic effects associated with immune check point inhibitors: asystematic review andmeta-analysis[J].JAMA Oncol,2018,4(12):1721-1728.[16]Yuen CA,Rezania K,Park DM,et al.Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy[J].Immunotherapy,2021,13(1):11-17.[17]Sato K,Mano T,Iwata A,et al.Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database[J].J Neurooncol,2019,145(1):1-9.[18]Johnson DB,Manouchehri A,Haugh AM,et al.Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study[J].J Immunother Cancer,2019,7(1):134.[19]Vogrig A,Mu?觡iz-Castrillo S,Joubert B,et al.Central nervous system complications associated with immune checkpoint inhibitors[J].J Neurol Neurosurg Psychiatry,2020,91(7):772-778.[20]Shibaki R,Murakami S,Oki K,et al.Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient[J].Jpn J Clin Oncol,2019,49(8):793-794.[21]Velasco R,Villagrán M,Jové M,et al.Encephalitis induced by immune checkpoint inhibitors: a systematic review[J].JAMA Neurol,2021,78(7):864-873.[22]Shimada T,Hoshino Y,Tsunemi T,et al.Neuromyelitis optica spectrum disorder after treatment with pembrolizumab[J].Mult Scler Relat Disord,2019,37:101447.[23]Xu M,Nie Y,Yang Y,et al.Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis[J].Neurologist,2019,24(3):75-83.[24]Kurashige T,Mito M,Yamamoto H,et al.Pembrolizumab-caused polyradiculoneuropathy as an immune-related adverse event[J].Neuropathology,2021,41(4):266-272.[25]Okada K,Seki M,Yaguchi H,et al.Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature[J].J Neurol,2021,268(2):680-688.[26]Touat M,Maisonobe T,Knauss S,et al.Immune checkpoint inhibitorrelated myositis and myocarditis in patients with cancer[J].Neurology,2018,91(10):e985-e994.[27]Anquetil C,Salem JE,Lebrun-Vignes B,et al.Immune checkpoint inhibitor-associated myositis[J].Circulation,2018,138(7):743-745.[28]Moreira A,Loquai C,Pf?觟hler C,et al.Myositis and neuromuscular side-efects induced by immune checkpoint inhibitors[J].Eur J Cancer,2019,106:12-23.[29]Sechi E,Markovic SN,McKeon A,et al.Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profles and outcomes[J].Neurology,2020,95(17):e2442-e2452.[30]Brahmer JR,Abu-Sbeih H,Ascierto PA,et al.Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events[J].J Immunother Cancer,2021,9:e002435.[31]Dubey D,David WS,Reynolds KL,et al.Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum[J].Ann Neurol,2020,87(5):659-669.